Prostate cancer is the second most common cause of cancer mortality in men population. Multifactorial etiology, unpredictable course and outcome of the disease put survival determining factors of disease in the spotlight. One of new survival prognostic factors is Charlson Comorbidity Index – CCI. We presented basic characteristics of CCI, literature review regarding the CCI, as well as advantages and disadvantages of this index. CCI represents optimal balance between ease of use and prognostic capabilities. CCI value significantly contributes to better assessment of the long-term survival and the selection of appropriate cancer therapy.
Boyle P, Ferlay J. Cancer incidence and mortality in Europe. Ann Oncol. 2004;(3):481–8.
2.
Jemal A, Siegel R, Ward E. Cancer statistics. 2008;(2):71–96.
3.
Charlson M, Pompei P, Ales K, Mackenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases. 1987;(5):373–83.
4.
Kaplan M, Feinstein A. The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974;387–404.
5.
Valderas S, Jose M, Starfild B. Defining comorbidity: Implications for Understanding Health and Health Services. Annals of Family Medicine. 2009;(4):357–63.
6.
Jakovljević M, Ostojić L. Comorbidity and multimorbidity in medicine today: challenges and opportunities for bringing separated branches of medicine closer to each other. Psychiatr Danub. (Suppl 1):18–28.
7.
Lin B, Linn M, Gurel L. Cumulative illness raiting scale. J Am Geriatric Soc. 1968;622–6.
8.
Sharabiani M, Aylin P, Bottle A. Systematic review of comorbidity indices for administrative data. Medical Care. (12):1109–18.
9.
Rozzini R, Frisoni G, Ferrucci L. Geriatric Index of Comorbidity: Validation and comparison with other measures of comorbidity. Age and Ageing. 2002;(4):277–85.
10.
Groll D, To T, Bombardier C, Wright J. The development of a comorbidity index with physical function as the outcome. Journal of Clinical Epidemiology. 2005;(6):595–602.
11.
Litwin M, Greenfield S, Elkin E. Assessment of prognosis with the total illness burden index of prostate cancer. Cancer. 2007;(9):1777–83.
12.
Charlson M, Szatrowski T. Validation of combined comorbidity index. J Clin Epidemiol. 1994;1245–51.
13.
Lee J, Lee D, Cho N. Impact of Charlson Comorbidity Index Varies by Age in Patients with Prostate Cancer Treated by Radical Prostatectomy: A Competing Risk Regression Analysis. Ann Surg Oncol. 2014;677–83.
14.
Daskivich T, Chamie K, Kwan L. Comorbidity and competing risks for mortality in men with prostate cancer. Cancer. 2011;4642–50.
15.
Kastner C, Armitage J, Kimble A. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting. Prostate Cancer and Prostatic Diseases. 2006;270–4.
16.
Goyal J, Pond G, Galsky M. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations. 2014;(36):27–34.
17.
Guzzo T, Dluzniewski P, Orosco R. Prediction of Mortality After Radical Prostatectomy by Charlson Comorbidity Index. Urology. 2010;553–8.
18.
Fowler J, Terrell F, Refroe L. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol. 1996;1714–8.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
